The expression of PRs has been reported as a key factor that is associated with prognosis and drug-resistance of endometrial cancer [127,128] The well-differentiated endometrial cancer usually presented with PR, which may maintain the effect of hormone therapy, such as medroxyprogesterone acetate. The gene discussed is PGR; the disease is endometrial cancer.